Clinical results of a GLP-1 in pill form showed safety and efficacy data similar to blockbuster injectable drugs.

The agency is missing deadlines and not responding to biotech companies, forcing some to push back clinical trials.

In his first major action on health care costs this term, President Donald Trump issued a multi-part executive order on ...

Many of the directions included in the order will be familiar to those who watched drug pricing policy closely during the ...

A new executive order signed Tuesday by President Trump directs Congress to change a key provision of the law allowing ...

The president said he would build on the Medicare drug-price negotiation program begun under Joe Biden, but supports a change ...

The U.S. Food and Drug Administration on Monday warned consumers and pharmacies that fake versions of Ozempic, a drug to ...

Eli Lilly's Phase 3 study highlights the effectiveness of Orforglipron in lowering blood sugar and promoting weight loss, ...

The FDA is phasing out an animal testing requirement for monoclonal antibody therapies in favor of testing drugs on ...

In an April 14 announcement, the FDA stated that Novo Nordisk — manufacturer of Ozempic and Wegovy — notified the agency that “several hundred units of counterfeit Ozempic (semaglutide) injection 1 mg ...

HHS Secretary Robert F. Kennedy Jr.’s sweeping layoffs across federal health agencies are disrupting the work of drug, ...